Arbor Biotechnologies

What Arbor Biotechnologies does

Arbor Biotechnologies is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing next-generation gene editing therapeutics for genetic diseases, founded in 2016 by Feng Zhang, David Walt, David Scott, and Winston Yan. The company has built what it describes as the most extensive proprietary toolbox of CRISPR-based genomic editors in the industry — spanning Cas13d, Cas12g, Cas12h, Cas12i, Fanzor-based, IsrB-based, and reverse transcriptase editing systems — discovered through an AI/ML-driven discovery engine that mines a database of billions of proteins combined with high-throughput screening and protein engineering. Lead clinical asset ABO-101, an in vivo gene editor for primary hyperoxaluria type 1 (PH1), entered Phase 1/2 dosing at Mayo Clinic in July 2025 and carries FDA Orphan Drug, Rare Pediatric Disease, and IND-clearance designations.

Arbor pursues a partnership-first go-to-market strategy rather than direct commercialization. It licenses its proprietary editors and platform to large pharmaceutical and biotech counterparties — including Vertex (up to $1.2B in potential payments across multiple programs), Chiesi ($115M committed), 4DMT (50:50 co-development for CNS/ALS), Allogene, Lonza, EdiGene, TCR2, and Vor Biopharma — generating revenue through upfront fees, research funding, milestone payments, and tiered royalties, while also building an internal pipeline in liver (PH1) and CNS (ALS) diseases using LNP (Acuitas) and AAV (4DMT) delivery technologies. Total disclosed funding exceeds $300M across Series A ($15.6M, 2017), Series B ($215M, 2021), and Series C ($73.9M, 2025), with additional strategic investment from Samsung Life Science Fund in October 2025.

The business model is structurally a clinical-stage biotech augmented by a licensing and collaboration engine. Arbor combines its own pipeline (e.g., ABO-101, ABR-004 for PCSK9 in NHPs, ALS gene editing program) with non-dilutive partnership capital and milestone economics, expanded in 2024 through the acquisition of Serendipity Biosciences to incorporate Fanzor/IsrB programmable editing assets. Headcount has grown from 40+ (2019) to 130 (2022) with implied continued expansion through 2025–2026, supporting clinical execution and platform R&D.

Name

Arbor Biotechnologies

Legal name

Arbor Biotechnologies, Inc.

Website

https://arbor.bio

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Arbor Biotechnologies is a clinical-stage biotech that develops a proprietary AI-driven toolbox of next-generation CRISPR gene editors to treat genetic diseases, licensing its platform to pharma partners while advancing an internal pipeline led by ABO-101 for primary hyperoxaluria type 1.

Ownership category

akta.pro rank

Product category

Gene Editing Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Gene editing therapeutics
• CRISPR-based medicines
• Biopharmaceutical licensing
• Genomic medicine platform
• Rare disease therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments: Arbor licenses its proprietary CRISPR gene editing technologies to pharmaceutical and biotech partners (Vertex, Allogene, Lonza, EdiGene, TCR2, etc.), receiving upfront payments, research/development/regulatory/commercial milestone payments, and tiered royalties on net sales of royalty-bearing products.
2. Strategic Collaboration Payments: Arbor enters into multi-year strategic research collaborations where partners pay for access to Arbor's technology platforms, with potential payments up to $1.2 billion across multiple programs (Vertex 2021 deal). Includes upfront cash payments, milestone payments, and royalty structures.
3. Equity Financing (VC Funding): Arbor raises equity capital through venture funding rounds (Series A $15.6M in 2017, Series B $215M in 2021, Series C $73.9M in 2025) to fund R&D and clinical advancement. Total raised exceeds $300M.
4. Partnership Upfront and Milestone Fees: Chiesi Group committed $115 million upfront as part of a global strategic partnership to develop rare disease gene editing programs, with additional milestone and royalty payments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

Arbor Biotechnologies is a clinical-stage biotechnology company that discovers, engineers, and develops a proprietary toolbox of next-generation CRISPR-based genomic editors for therapeutic applications in genetic diseases. The company combines an AI/ML-driven discovery engine with high-throughput screening to identify novel nucleases, reverse transcriptases, and other editing tools, then advances these through internal therapeutic programs (lead candidate ABO-101 for primary hyperoxaluria type 1) and strategic licensing partnerships with pharmaceutical and biotech companies.

Product overview

Arbor Biotechnologies is a next-generation gene editing company developing a diversified toolbox of proprietary CRISPR-based genomic editors and precision gene editing technologies. The company's core offerings include its AI/ML-driven discovery engine that has generated the most extensive portfolio of wholly-owned CRISPR nucleases in the industry, including Cas13d, Cas12g, Cas12h, and Cas12i systems. Lead clinical programs include ABO-101 (for primary hyperoxaluria type 1) and ABR-004 (compact nuclease), with additional pipeline programs in ALS and CNS diseases. The technology platform enables capabilities spanning gene knockout, reverse transcriptase editing, precise excisions, and large DNA insertions, with strategic partnerships including Vertex, 4DMT, Chiesi Group, and Allogene.

Differentiator

Problem solved

Functional benefit

Products and services

• ABO-101
• ABR-001
• ABR-004
• ALS Gene Editing Program

Quantifiable outcome

• ABO-101 demonstrated therapeutically relevant reduction in urinary oxalate in PH1 preclinical mouse models and efficient HAO1 editing in NHPs with preserved genomic integrity
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature8 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based therapeutics across hemoglobinopathies, oncology, and regenerative medicine. It is the most direct competitor to Arbor, with a similar partnership-heavy model and overlapping indications in liver and ex vivo cell therapy.
• Editas Medicine: Editas Medicine is a clinical-stage CRISPR gene editing company developing in vivo and ex vivo therapeutics, including EDIT-101 for LCA10 — the first in vivo CRISPR IND, filed by Arbor COO Pam Stetkiewicz while at Editas. Direct competitor in gene editing modality and indication space.
• Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 therapeutics (NTLA-2001 for ATTR, NTLA-2002 for HAE) using LNP delivery — the same liver-targeted modality as Arbor's ABO-101. Direct competitor in in vivo liver gene editing.
• Beam Therapeutics: Beam Therapeutics is a clinical-stage company developing base editing therapeutics for genetic diseases, with programs in sickle cell disease, T-cell leukemia, and liver indications. Competes with Arbor's precision gene editing approach using a different editing chemistry.
• Verve Therapeutics: Verve Therapeutics is developing in vivo base editing therapies for cardiovascular disease, with lead program VERVE-102 targeting PCSK9 — the same target as Arbor's ABR-004 program. Direct competitor in cardiovascular gene editing using a similar in vivo liver editing modality.
• Prime Medicine: Prime Medicine is a clinical-stage biotechnology company developing prime editing therapeutics — a search-and-replace gene editing technology that competes directly with Arbor's precision editing approach for treating genetic diseases.
• Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR gene editing company developing allogeneic CAR-T cell therapies (CB-010 and others) using its chRDNA platform. Direct peer in CRISPR-based cell therapy applications, similar to Arbor's partnerships with Allogene and TCR2.

Emerging players

• Tessera Therapeutics: Tessera Therapeutics is developing Gene Writing — a new genome engineering technology that can make precise insertions, deletions, and substitutions in the genome. Emerging competitor with potential overlap to Arbor's RT editing and large insertion capabilities.

Broad incumbents

• Sangamo Therapeutics: Sangamo Therapeutics is a clinical-stage genomic medicine company with a broader portfolio including zinc finger nucleases, AAV-based gene therapy, and cell therapy. While it predates CRISPR, it represents an incumbent genomic medicine player pursuing overlapping rare disease indications.

Others

• Ginkgo Bioworks: Ginkgo Bioworks is a horizontal platform for cell programming and biosecurity that has partnered with Arbor on discovery and development of precision gene editors. Ginkgo provides cell engineering and high-throughput screening infrastructure that supports Arbor's AI-guided protein engineering pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/arbortx
• LinkedInlinkedin.com/company/arborbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arbor Biotechnologies